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Conclusion 
This was the first randomized pharmacological drug trial 
in RIP. No significant therapeutic effect of PENTOCLO was 
detected. There is a need to develop more sensitive 
measures to detect the effect of investigational drugs in 
RIP.   
 
PV-0042 Radiation related lymphopenia as a predictor 
of locoregional recurrence in early breast cancer 
O. Cho1, Y. Oh1, M. Chun1, O.K. Noh1, J. Heo1 
1Ajou University Hospital, Radiation Oncology, Suwon 
City, Korea Republic of  
 
Purpose or Objective 
Many studies reported that radiation related lymphopenia 
(RRL) was associated with treatment outcome in various 
cancers. However association between RRL and treatment 
outcome in early breast cancer (EBC) was rarely studied. 
This study aimed to investigate whether RRL could predict 
clinical outcome in EBC patients. 
Material and Methods 
We analyzed 216 EBC patients (stage IA-IIB) treated with 
adjuvant radiotherapy (RT) after partial mastectomy from 
2004 to 2012 in our institution using Kaplan-Meier plots 
and the Cox proportional hazards model. All patients did 
not receive chemotherapy. Peripheral absolute 
lymphocyte counts (ALCs) during two years after RT were 
collected from each patient. They were divided into 
pretreatment ALC (ALC0), ALC 3-5 months (ALC1), ALC 9-
11 months (ALC2), ALC 15-17 months (ALC3), and ALC 21-
23 months (ALC4) after RT.  
Results 
ALCs after RT had a tendency of slow increase after rapid 
decline (median [range] ALC0 1847 cells/μL [623-4085], 
ALC1 1479 cells/μL [437-3500], ALC2 1626 cells/μL [775-
3193], ALC3 1730 cells/μL [854-4408], and ALC4 1855 
cells/μL [899-3793]). The 86 patients with ALC1≤1400 
cells/μL had significantly lower 8 years locoregional 
control rate than 118 patients with ALC1>1400 cells/μL 
(80.5% vs. 98.3%, P=0.012) while there was no difference 
in 8 years disease specific survival rate between two 
groups (98% vs. 97.1%, P=0.758). Young age (≤40 years), 
lymphopenia (ALC1≤1400 cells/μL), and high histologic 
grade were significant predictors of locoregional 
recurrence (LRR) in multivariate analysis (hazard ratio 
[97% confidence interval] 1.39 [1.18-13.7] P=0.026, 1.74 
[1.21-26.8] P=0.028, and 2.3 [2.6-38.4] P<0.001). 
Conclusion 
Low ALCs 3-5 months after RT were associated with LRR in 
EBC patients. Therefore RRL could be a potential predictor 
for LRR of EBC. 
 
   
PV-0043  ESTRO guidelines for volume delineation for 
RT after immediate implant-based reconstruction 
O. Kaidar-Person1, P. Poortmans2, B.V. Offersen3 
1Rambam Health Care Campus - Faculty of Medicine, 
Oncology Institute, Haifa, Israel; 2Institut Curie, 
Radiation Oncology, Paris, France; 3Aarhus University 
Hospital, Oncology, Aarhus, Denmark  
 
Purpose or Objective 
on behalf of the ESTRO Working Group on Breast 
reconstruction and radiation therapy: a contouring 
project. 
Immediate breast reconstruction is increasingly used after 
mastectomy, even if radiation therapy (RT) is indicated. 
Contouring guidelines in case of postmastectomy RT 
(PMRT) after implant-based immediate breast 
reconstruction are missing (IBR-i). We developed 
delineation guidelines based on a consensus between a 
global group of breast cancer experts. 
Material and Methods 
After designing the project by the core group ,an 
invitation letter was sent to an international 
multidisciplinary group of experts (including breast 
surgeons, radiation oncologists, and clinical oncologists) 
inviting them to participate in the consensus guidelines. 
The project included: a web-questionnaire, contouring 
exercise, group discussions, and literature review.  
Results 
Based on mailings, the first contouring round, video 
conferences and a plenary discussion, guidelines are 
drafted to be validated in the prospective Danish DBCG RT 
Recon Trial randomising early breast cancer patients 
between immediate versus delayed breast reconstruction 
after mastectomy followed by loco-regional RT. 
Approximately 5-10% glandular tissue is retained after 
conventional total mastectomy, and more in cases of 
skin/nipple sparing mastectomy. Therefore, our 
recommendations include performing a careful evaluation 
of the patient using visualization/palpation, planning CT, 
and the extent of the contralateral breast (if intact), to 
determine the cranio-caudal borders of the CTV. The CTV 
includes the "residual breast tissue and the (subcutaneous) 
draining lymphatics", thereby excluding the implant.  
The location of the residual glandular tissue varies; in 
most cases it is found laterally in the breast, mainly in the 
“axillary-tail”. We recommend consulting with the breast 
surgeon about the anatomical borders of the breast-skin. 
Moreover, in cases of a muscle flap/implant procedure, 
the transplanted flap including its overlaying skin is not 
part of the target volume, for which the scars should be 
marked for proper delineation. 
The implant and the contralateral breast should be 
delineated on planning CT as well as all other organs at 
risk for treatment planning 
 purposes. 
Table 1: ESTRO delineation guidelines for the CTV in case 
of implant-based immediate breast reconstruction 
Figure 1: Retro-pectoral implant. The CTV is delineated in 
pink. 
Conclusion 
The use of target volume guidelines in the setting of IBR-
i, based on recognised zones of tumour recurrence risk, 
aims to reduce inter- and intra-observer variation. They 
should be reserved for cases for which the disease staging 
(mainly T-stage) and surgical procedures used are well-
defined. These guidelines are being validated in the DBCG 
reconstruction trial. 
 
PV-0044  Mastectomy or breast-conserving therapy for 
early breast cancer: outcome comparison of 7565 
cases 
S. Corradini1, M. Pazos1, D. Reitz1, S. Schönecker1, M. 
Niyazi1, U. Ganswindt1,2, F. Alongi3,4, M. Braun5, N. 
Harbeck6, C. Belka1 
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1LMU Munich, Department of Radiation Oncology, 
Munich, Germany ; 2Medical University, Department of 
Radiation Oncology, Innsbruck, Austria ; 3Hospital Sacro 
Cuore Don Calabria, Department of Radiation Oncology, 
Negrar, Italy ; 4University of Brescia, Radiation 
Oncology, Brescia, Italy; 5Red Cross Hospital, Breast 
Centre, Munich, Germany; 6LMU Munich, Department of 
Obstetrics and Gynecology- Breast Centre, Munich, 
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Purpose or Objective 
Treatment of early stage breast cancer (BC) can be 
considered as a preference-sensitive care, where decision-
making between treatment options can vary according to 
patient preferences. Typical factors that influence 
therapy choice in favour of mastectomy include: concerns 
about cancer recurrence or perceived consequences 
related to breast conserving surgery (BCT), including 
potential adverse effects of radiation therapy. Aim of the 
present study was to compare the oncologic outcome of 
mastectomy versus breast conserving therapy in patients 
treated in a modern clinical setting outside of clinical 
trials. 
Material and Methods 
Data were provided by the population-based Munich 
Cancer Registry. Between 1998 and 2014, all female 
patients diagnosed with early invasive BC (pT1pN0, 
pT2pN0, pT1pN1 and pT2pN1) and treated at two Breast 
Care Centres were included in this observational study. 
For comparison of the standard BCT and mastectomy 
approaches, we excluded patients with more than 3 
positive lymph nodes (pN2) as postmastectomy RT (PMRT) 
would have been routinely recommended in these high-
risk patients.  
Results 
The final study cohort consisted of 7565 women with a 
median follow-up of 95.2 months. After adjusting for age, 
tumour characteristics and therapies, Cox regression 
analysis for local recurrence-free survival identified BCS 
with RT as an independent predictor for improved local 
control (hazard ratio [HR], 1.476; 95% confidence interval 
[CI], 1.164-1.872, p<0.001) as compared to mastectomy 
without RT. Ten-year risk of local recurrences was 8.7% 
following BCS, compared to 14.8% in patients receiving 
mastectomy (p<0.001). Similarly, lymph node recurrences 
(10y LNR 2.4% vs 6.7%, p<0.001) and distant metastasis 
(10y DM 9.8% vs 15.2%, p<0.001)) were more frequent in 
patients undergoing mastectomy only. This translated into 
an improved survival outcome among patients treated 
with BCS plus radiotherapy (10-year OS estimates 86.7% vs 
77.6%, p<0.001), which was also significant on 
multivariate analysis (p=0.011). 
Conclusion 
In conclusion, the present study showed that patients 
treated with BCS followed by radiotherapy in clinical 
practice had an improved outcome regarding local 
control, distant control and overall survival as compared 
to mastectomy alone in a large cohort reflecting "real-life" 
clinical practice in this setting. 
 
PV-0045  Is proton therapy a “pro” for breast cancer? 
A comparison of proton vs. non-proton RT using the 
NCDB 
M. Chowdhary1, A. Lee2, S. Gao3, P. Barry1, R. Diaz4, N. 
Bagadiya5, H. Park3, J. Yu3, L. Wilson3, M. Moran3, S. 
Higgins3, C. Knowlton3, K. Patel3 
1Rush University Medical Center, Radiation Oncology, 
Chicago, USA; 2SUNY Downstate Medical Center, 
Radiation Oncology, Brooklyn, USA; 3Yale School of 
Medicine, Therapeutic Radiology, New Haven, USA ; 
4Moffitt Cancer Center, Radiation Oncology, Tampa, 
USA; 5Emory University School of Medicine, Radiology, 
Atlanta, USA  
 
 
Purpose or Objective 
There is limited data demonstrating the clinical benefit of 
proton radiotherapy (PRT) in breast cancer. Here we 
investigate the impact of PRT on overall survival (OS) and 
evaluate predictors associated with PRT use for patients 
with breast cancer in the National Cancer Database 
(NCDB). 
Material and Methods 
Women with non-metastatic breast cancer treated with 
adjuvant radiotherapy from 2004-2014 were identified 
using the NCDB. Patients were stratified based on receipt 
of PRT or non-PRT (i.e. photons +/- electrons). A logistic 
regression model was used to determine predictors for PRT 
utilization. For OS, Multivariable analysis (MVA) was 
performed using Cox proportional hazard model. Subset 
analyses were performed for groups at risk for receiving 
higher heart dose. 
Results 
A total of 724,492 women were identified: 871 received 
PRT and 723,621 received non-PRT. 58.3% of the PRT 
patients were group stage 0-1. Median follow-up time was 
62.2 months. On multivariate logistic analysis, the 
following factors were found to be significant for receipt 
of PRT (all p<0.05): academic facility (odds ratio 
[OR]=2.50), South (OR=2.01) and West location 
(OR=12.43), left-sided (OR=1.21), ER-positive (OR=1.59), 
and mastectomy (OR=1.47); pT2-T4 disease predicted for 
decrease PRT use (OR=0.79).  
PRT was not associated with OS on MVA for all patients: 
Hazard Ratio: 0.85, p=0.168. PRT remained not significant 
on MVA after stratifying for subsets likely associated with 
higher heart radiation doses, including: left-sided 
(p=0.140), inner-quadrant (p=0.173), mastectomy 
(p=0.095), node positivity (p=0.680), N2-N3 disease 
(p=0.880), and lymph node irradiation (LNI) (p=0.767). 
Conclusion 
In this large national multicenter database, we found 
receipt of PRT to be associated with left-sided, ER+ 
tumors, mastectomy, South and West location, and 
academic facilities, but not higher group stages or LNI. 
PRT was not associated with OS, including in subsets likely 
at risk for higher heart doses. 
 In light of the high cost of proton RT, these data question 
the utilization of PRT, especially in early-stage patients 
with expected low heart doses, unless enrolled on a 
clinical trial. 
   
PV-0046  Patient selection for proton therapy of early 
breast cancer – the DBCG phase II study strategy 
L.B. Stick1, E.L. Lorenzen2, E.S. Yates3, C. Anandadas4, K. 
Andersen5, C. Aristei6, O. Byrne7, S. Hol8, I. Jensen9, A. 
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Verhoeven17, J. Vikström18, B.V. Offersen19 
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& Perugia General Hospital, Department of Surgical and 
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of Medical Physics, Aalborg, Denmark; 10The Royal 
Marsden Hospital NHS Foundation Trust and Institute of 
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Radiation Oncology, Paris, France ; 12Careggi University 
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Purpose or Objective 
Recently, overall survival gain from radiation therapy (RT) 
of the internal mammary nodes (IMN) was documented. 
IMN RT inevitably leads to more radiation dose to heart 
and lungs, thus often target coverage is compromised to 
meet constraints for doses to organs at risk (OAR). Here, 
doses to heart and lung are estimated when target 
coverage is not compromised in consecutive high-risk 
breast cancer (BC) patients. The aim is to establish dose 
cut-off points for selection of patients for proton therapy 
(PT) in the Danish Breast Cancer Group (DBCG) single-arm 
phase II trial. 
Material and Methods 
179 BC patients treated with adjuvant loco-regional RT 
including the IMN from 18 European departments were 
included in the study. Each department included 5 
patients with left-sided and 5 patients with right-sided BC. 
The prescription dose ranged from 39.9 Gy to 51.52 Gy in 
15 to 28 fractions.  Planning techniques included both 
conformal and several inversely optimized techniques (see 
Table 1). If the clinically delivered treatment plan did not 
comply with defined target coverage requirements, the 
plan was modified retrospectively for this study until 
sufficient target coverage was reached by allowing OAR 
constraints to be exceeded.  Sufficient target coverage 
was in this study defined as: V90% ≥ 95% of CTV_IMN, V90% 
≥ 95% of CTVn and V95% ≥ 95% of CTVp_breast/chest wall. 
 
 
 
Results 
Forty percent of the treatment plans needed modification 
to fulfil the required dose for target coverage. Median 
mean heart dose (MHD) was 3.0 Gy (range, 1.1-8.2 Gy) for 
left-sided BC and 1.4 Gy (range, 0.4-11.5 Gy) for right-
sided BC. For left-sided BC patients the median MHD was 
2.8 Gy (range, 1.1-7.4 Gy) when breath hold (BH) was used 
(71%) and 5.2 Gy (range, 2.2-8.2 Gy) when no BH was used 
(29%). Median mean (ipsilateral) lung dose was 13.4 Gy 
(range, 5.1-24.9 Gy). Median V17Gy/V20Gy 
(hypofractionated/normofractionated plans) for lung was 
31% (range, 0-57%).  To guide selection criteria for referral 
to PT, we chose to set cut-off points for dose to OAR for 
departments that aimed for treating all patients with 
3DCRT and in BH, which 9 departments did (98% 3DCRT 
and 93% BH). We chose MHD ≥ 4 Gy or lung V17Gy/V20Gy 
≥ 37% as cut-off points for the PT study based on dose-
response relationships for ischemic heart disease and 
radiation pneumonitis in combination with capacity 
limitations for PT. In the departments having 3DCRT and 
BH as standard, 22% of the patients had a MHD ≥ 4 Gy or 
lung V17Gy/V20Gy ≥ 37%. The remaining 9 departments 
mainly used inverse techniques (98%) where BH was used 
in 31% of the patients. Fifty-two percent of these patients 
had a MHD ≥ 4 Gy or lung V17Gy/V20Gy ≥ 37%. 
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Purpose or Objective 
Recently, overall survival gain from radiation therapy (RT) 
of the internal mammary nodes (IMN) was documented. 
IMN RT inevitably leads to more radiation dose to heart 
and lungs, thus often target coverage is compromised to 
meet constraints for doses to organs at risk (OAR). Here, 
doses to heart and lung are estimated when target 
coverage is not compromised in consecutive high-risk 
breast cancer (BC) patients. The aim is to establish dose 
cut-off points for selection of patients for proton therapy 
(PT) in the Danish Breast Cancer Group (DBCG) single-arm 
phase II trial. 
Material and Methods 
179 BC patients treated with adjuvant loco-regional RT 
including the IMN from 18 European departments were 
included in the study. Each department included 5 
patients with left-sided and 5 patients with right-sided BC. 
The prescription dose ranged from 39.9 Gy to 51.52 Gy in 
15 to 28 fractions.  Planning techniques included both 
conformal and several inversely optimized techniques (see 
Table 1). If the clinically delivered treatment plan did not 
comply with defined target coverage requirements, the 
plan was modified retrospectively for this study until 
sufficient target coverage was reached by allowing OAR 
constraints to be exceeded.  Sufficient target coverage 
was in this study defined as: V90% ≥ 95% of CTV_IMN, V90% 
≥ 95% of CTVn and V95% ≥ 95% of CTVp_breast/chest wall. 
 
 
 
Results 
Forty percent of the treatment plans needed modification 
to fulfil the required dose for target coverage. Median 
mean heart dose (MHD) was 3.0 Gy (range, 1.1-8.2 Gy) for 
left-sided BC and 1.4 Gy (range, 0.4-11.5 Gy) for right-
sided BC. For left-sided BC patients the median MHD was 
2.8 Gy (range, 1.1-7.4 Gy) when breath hold (BH) was used 
(71%) and 5.2 Gy (range, 2.2-8.2 Gy) when no BH was used 
(29%). Median mean (ipsilateral) lung dose was 13.4 Gy 
(range, 5.1-24.9 Gy). Median V17Gy/V20Gy 
(hypofractionated/normofractionated plans) for lung was 
31% (range, 0-57%).  To guide selection criteria for referral 
to PT, we chose to set cut-off points for dose to OAR for 
departments that aimed for treating all patients with 
3DCRT and in BH, which 9 departments did (98% 3DCRT 
and 93% BH). We chose MHD ≥ 4 Gy or lung V17Gy/V20Gy 
≥ 37% as cut-off points for the PT study based on dose-
response relationships for ischemic heart disease and 
radiation pneumonitis in combination with capacity 
limitations for PT. In the departments having 3DCRT and 
BH as standard, 22% of the patients had a MHD ≥ 4 Gy or 
lung V17Gy/V20Gy ≥ 37%. The remaining 9 departments 
mainly used inverse techniques (98%) where BH was used 
in 31% of the patients. Fifty-two percent of these patients 
had a MHD ≥ 4 Gy or lung V17Gy/V20Gy ≥ 37%. 
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Conclusion 
Using thresholds of MHD ≥ 4 Gy and lung V17Gy/V20Gy ≥ 
37% in departments using 3DCRT and BH, we estimate that 
22% of all the patients requiring loco-regional IMN RT will 
be eligible for the DBCG phase II PT study. 
 
PV-0047 IMRT versus VMAT for elderly patients with 
breast cancer: comparison of acute and late toxicities 
F. Alongi1,2, F. Gregucci1, A. Fiorentino1, R. Mazzola1, V. 
Figlia1, F. Ricchetti1, G. Sicignano1, N. Giaj-Levra1, S. 
Naccarato1, A. Massocco1, S. Corradini3, R. Ruggieri1 
1Hospital Sacro Cuore Don Calabria- Cancer Care Center, 
Radiation Oncology, Negrar, Italy ; 2University of 
Brescia, Radiation Oncology, Brescia, Italy; 3LMU 
University Hospital, Radiation Oncology, Munich, 
Germany  
 
Purpose or Objective 
To evaluate the differences between conventional 
fractionated intensity modulated radiotherapy (cIMRT)  
and hypofractionated (HypoRT) volumetric modulated arc 
therapy (VMAT) in elderly women affected by early stage 
Breast Cancer (BC) in terms of RT-related acute and late 
side effect. 
Material and Methods 
Between October 2011 and July 2015, 80 consecutive 
 elderly BC patients were treated with cIMRT for 5 weeks 
(40 patients) or HypoRT-VMAT for 3 weeks (40 patients). 
Inclusion criteria were: age ≥ 70 years, early stage BC 
(pT1-2 pN0-1), no prior neoadjuvant chemotherapy and 
non-metastatic disease. For patients receiving cIMRT or 
HypoRT-VMAT, a total dose of 50 Gy (25 fractions) or 40.5 
Gy (15 fractions) were prescribed to the whole ipsilateral 
breast, respectively. All patients received a 
simultaneously integrated boost (SIB) up to a total dose of 
60 Gy for cIMRT and 48 Gy for HypoRT-VMAT. Acute and 
late side effects were evaluated using the RTOG/EORTC 
radiation morbidity scoring system. 
Results 
Median follow-up was 45 months. Compliance to 
treatment was 100% for each RT schedule, without any 
interruptions. The median age was 75 years (range 70-83). 
The median PTV breast was 929 cc (range 330–2527). In 
each group, 90% and 92% of patients received hormone-
therapy, respectively. During RT delivery, only low grade 
acute skin toxicity was observed, with an advantage for 
the HypoRT-VMAT group: grade 1 in 25 cases (62.5%) of the 
cIMRT group and 21 cases (52.5%) of the HypoRT-VMAT 
group (p=0.2); while grade 2 toxicity was reported in 10 
cIMRT patients (25%) and 1 HypoRT-VMAT patient (2.5%) 
(p=0.001). No skin G3 or other side effects were observed 
at all. Regarding late adverse events, skin toxicity was 
overall mild without any grade 2 or higher toxicity, but 
resulted in significantly better outcome for patients 
treated with HypoRT-VMAT. Grade 1 side effects were 
reported in 13 cases (32.5%) of the cIMRT group as 
compared to 2 cases (5%) of the VMAT group (p=0.001). G1 
fibrosis was registered in 4 cIMRT (10%) cases and 2 
HypoRT-VMAT patients (5%) (p=0.4). No other late 
toxicities (e.g. pulmonary or arm edema) were observed. 
In patients treated with cIMRT, only the breast volume 
>700 cc was statistically associated with acute G2 skin 
adverse events (p=0.04). In patients receiving Hypo-RT, 
factors like age or breast volume did not have any 
influence on the onset of acute or late skin toxicity. No 
differences in fatigue were observed for the two groups of 
treatment groups: 11 cIMRT patients vs 16 HypoRT-VMAT 
(p=0.1). 
Conclusion 
The present study showed that whole breast cIMRT and 
HypoRT-VMAT are feasible and well tolerated in early 
stage BC elderly patients and that HypoRT-VMAT is 
affected by lower risk of acute and late RT-related side 
effects. 
 
PV-0048 The Radiosensitivity Index (RSI) predicts for 
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Lee4, L.B. Harrison2, T.J. Robinson2, J.F. Torres-Roca2, R. 
Diaz2 
1University of South Florida, Morsani College of 
Medicine, Tampa, USA ; 2Moffitt Cancer Center, 
Department of Radiation Oncology, Tampa, USA; 
3Baycare Morton Plant Hospital, Department of Breast 
Oncology Surgery, Clearwater, USA ; 4Moffitt Cancer 
Center, Department of Breast Oncology, Tampa, USA  
 
Purpose or Objective 
While genomic biomarkers have been utilized to predict 
outcomes in ER+ breast cancer, further investigation is 
needed to develop similar predictors for triple negative 
breast cancer (TNBC). RSI is a previously validated multi-
gene expression index that is thought to be radiotherapy 
(RT)-specific. Here, we evaluate whether RSI is an RT-
specific predictive biomarker in TNBC. 
Material and Methods 
Prospectively gathered breast tumor samples were 
identified from an IRB-approved tissue biorepository 
representing one academic and two community hospitals. 
Gene expression of tumor samples was assessed with 
Affymetrix microarray chips and the RSI 10-gene signature 
was calculated for each sample using the previously 
published rank-based algorithm. As in prior studies, 
radiophenotype was determined by dichotomizing at 
RSI=0.3745, where RSI≥0.3745 is radioresistant (RR) and 
RSI<0.3745 is radiosensitive (RS). Clinical information was 
obtained by chart review. Endpoints were locoregional 
recurrence-free survival (LRFS), distant metastasis-free 
survival (DMFS), overall survival (OS), and progression-free 
survival (PFS). Outcomes were estimated with Kaplan 
Meier (KM) methods and compared with log-rank tests. 
Associations between characteristics and outcomes were 
explored with univariable (UVA) and multivariable (MVA) 
Cox regression. 
Results 
97 TNBC tumors with available genomic profiling were 
identified for analysis. The median age was 55 years 
(range 25-82). 97.9% of tumors were pT1-T2, and 37.1% 
had positive lymph nodes. 80% of tumors were high grade. 
40.2% were treated with mastectomy alone, 14.4% with 
